SLC7A1 and cardiovascular disorder: Using a structure-based design, Xu and colleagues synthesized two pan-ERR agonists, SLU-PP-332 and SLU-PP-915, each of which significantly improved the ejection fraction, reduced fibrosis and enhanced survival in models of pressure overload-induced HF without affecting cardiac hypertrophy.409 Targeting other nuclear receptors, such as RARs, PPARs, and LXRs, has also shown promise for ameliorating cardiovascular disease.410,411 These findings provide strong pharmacological evidence supporting the potential of targeting NRs for cardiovascular disease management.